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Abstract 
Cutaneous melanoma arises from the malignant transformation of melanocytes. Is 
the least common of the three main types of skin cancer (<5%), but is a very 
aggressive malignancy, being responsible for the majority of skin cancer-related 
deaths. Nowadays, available therapies still have limitations due to rapidly 
acquirement of resistance and adverse secondary effects, resulting in high 
mortality. As cutaneous melanoma cells evidence the presence of the Warburg 
effect and deregulation of MAPK and PI3K/AKT/mTOR pathways, we hypothesize 
that the metabolic modulator DCA, in combination with MAPK or mTOR inhibitors, 
can be a promising new therapy for melanoma patients. The present work 
describes the major effects observed on cell viability, cell proliferation, cell cycle, 
apoptosis, and downregulation of MAPK and mTOR pathways, after treatment with 
DCA, with a BRAFV600 inhibitor (vemurafenib) and with an mTOR inhibitor 
(RAD001), either alone or in combination, in melanoma cell lines with different 
genetic background. DCA combined with vemurafenib appear to be the more 
efficient treatment, particularly in the BRAFV600 cell line. Also the MAPK and 
mTOR pathway inhibitors seem to have effects on cell dynamics that were highly 
potentiated when combined with DCA. Combination of vemurafenib and RAD001 
also evidence promising effects, however, the activation of secondary survival 
pathways seems to occur. In the present study we obtained strong evidences that 
resistance to vemurafenib can be reversed through combination of BRAF inhibition 
with a metabolic modulator as DCA. Our work reinforces that the BRAF mutational 
status can be useful as a therapy predictive marker, in order to perform a 
personalized therapy that may improve the survival of patients with cutaneous 
melanoma. 
Resumo 
O melanoma cutâneo desenvolve-se a partir da transformação maligna dos 
melanócitos. É o menos comum dos três principais tipos de cancro de pele (<5%), 
sendo, no entanto, o mais agressivo e responsável pela maioria das mortes 
relacionadas com o cancro da pele. Atualmente as terapias disponíveis 
apresentam limitações, como seja a rápida aquisição de resistência e efeitos 
secundários adversos, permanecendo a mortalidade elevada. O facto de as 
células de melanoma cutâneo evidenciarem a presença do efeito de Warburg e 
desregulação de vias de sinalização das MAPK e PI3K/AKT/mTOR, parece 
indicar que o modulador de metabolismo DCA, em combinação com inibidores 
destas vias, poderá ser uma terapia promissora para pacientes com melanoma. O 
presente trabalho descreve os principais efeitos observados sobre a viabilidade e 
a proliferação celular, ciclo celular, apoptose e bloqueio das vias das MAPK e 
mTOR, após tratamento com DCA, com o inibidor de BRAFV600 (vemurafenib) e 
com o inibidor de mTOR (RAD001), isoladamente ou em combinação, em linhas 
celulares de melanoma com diferente perfil genético. Os resultados obtidos 
parecem indicar que o DCA poderá ser um agente terapêutico eficiente no 
tratamento do melanoma cutâneo, quer isoladamente ou em combinação com os 
outros fármacos. O DCA em combinação com vemurafenib aparenta ser o 
tratamento mais eficiente, particularmente na linha celular com a mutação 
BRAFV600. Os inibidores das vias das MAPK e do mTOR também afetaram a 
dinâmica celular, sendo o efeito maior quando combinados com o DCA. A 
combinação do vemurafenib com o RAD001 também demonstrou efeitos 
promissores, no entanto, parece levar à ativação de vias de sobrevivência 
secundárias. Foram obtidas evidências de que a resistência ao vemurafenib 
poderá ser revertida através da inibição do BRAF em combinação com um 
modulador do metabolismo, como seja o DCA. Este trabalho reforça o estado 
mutacional do BRAF como um possível marcador terapêutico, o que permitirá o 
desenvolvimento de uma terapia mais personalizada, que poderá conduzir a uma 
maior sobrevivência dos pacientes com melanoma cutâneo.  
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1 Introduction 
1.1 Skin cancer 
Skin is the largest organ of the human body, representing almost 20% of the body 
mass. Covering our entire body, skin provides the first protection barrier against 
external damage, such as pathogens and UV radiation. Excess of sunlight 
exposure in combination with other aggressive agents, can generate severe skin 
diseases particularly skin cancer [1]. According to the World Health Organization 
(WHO), there are three types of skin cancer that can be subdivided in two major 
groups: non-Melanoma skin cancers and Malignant Melanoma. Non-Melanoma 
skin cancers are rarely lethal and are surgical treated, comprising Basal Cell 
Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) [1]. BCCs are the most 
common type and rarely metastasize, while SCCs, although less common and 
treatable in the majority of the cases, can cause patients death.  
 
1.2 Melanoma 
Melanoma is the least common of the three main types of skin cancer (<5%), but 
is responsible for more than 80% of all skin cancer-related deaths [1, 2]. Malignant 
melanoma may occur de novo, without a precursor lesion, or in 20-30% of the 
cases may develop from pre-existing melanocytic nevi, which are benign 
proliferations of melanocytes [3, 4]. Melanocytes are neural crest-derived cells that 
during development colonize mainly the skin, eye and less often other tissues 
throughout the body, as inner ear and leptomeninges [5, 6]. These pigment 
producing cells exist in a lower proportion comparing with the basic skin units, 
keratinocytes (1 to 35, respectively), and are responsible for the production and 
export of melanin, the light absorbing pigment [7-9]. Once produced, melanin is 
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delivered from melanocytes to keratinocytes that use it to protect their nucleus 
from UV radiation-induced DNA damage, reactive oxygen species, metal ions, 
drugs and organic chemicals [10, 11]. Arising from the malignant transformation of 
melanocytes, melanoma can occur in any tissue that contains melanocytes, being 
skin the most common site for melanoma development, followed by the eye. 
Melanoma can be divided in cutaneous or ocular according to the location of the 
trigger melanocyte [12]. Ocular melanoma is the most common primary eye tumor 
in adults, although only accounting for approximately 5% of all melanomas [13]. 
The majority appears in the uvea (>95%), being the conjunctival melanoma less 
frequent (<5%) [14]. Cutaneous melanoma is a very aggressive malignancy, and 
one of the most common cause of cancer death in young adults [15-17].  
 
1.2.1 Epidemiology of cutaneous melanoma 
The levels of melanoma incidence are variable worldwide (Fig. 1). Generally, 
increases with increasing proximity to the equator, where Caucasians are 
predominant, being exposure to ultraviolet radiation the most important 
environmental risk factor for cutaneous melanoma [18, 19]. 
Reporting an increase of incidence in the past decades, cutaneous melanoma 
became an “epidemic cancer”. Global incidence in 2012 was 232 000 comparing 
with 197 000 in 2008, with different geographical, gender and age distribution [20, 
21]. Improved criteria for diagnosis allows clinicians to perform a better scrutiny 
with more pigmented lesions biopsied, a far more accurately recognition of 
melanomas and at earlier stages, thereby raising the number of diagnosed 
melanomas [20]. Mortality also raised in the last years with values near 46 000 in 
2008 and almost 55 500 in 2012 [21].  
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Figure 1: Worldwide incidence of cutaneous melanoma in 2012 (rate/ 100,000 individuals, for both 
sexes and all ages). The highest incidence occurs in Australia, followed by Europe, New Zealand 
and North America (www.globocan.iarc.fr). 
 
1.2.2 Predisposition and risk factors for cutaneous melanoma 
Beside environmental factors, such as UV radiation, others like individual features 
and genetic predisposition, play a role in determining melanoma risk [22]. Fair 
skin, red hair, blue eyes, freckles and multiple benign or dysplastic nevi are the 
individual features associated with increased risk [23-26]. Rarely, cutaneous 
melanoma appears in a familial context (8-12% of all melanomas) [27]. Mutations 
on CDKN2A and CDK4 genes are considered genetic predisposition events for 
familial melanoma development [28, 29]. Further prognostic factors for sporadic 
melanoma are based on patient age and gender, tumor location, level of invasion 
and tumor vascularity [30, 31]. Better prognosis fits with young age, female, thin 
localized disease, low mitotic rate and absence of ulceration [18]. 
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1.2.3 Clinical aspects of cutaneous melanoma 
Clinically, cutaneous melanoma is classified in four major subtypes based on 
anatomic localization, type of skin, sun-exposure and growth pattern (Table 1). 
Lentigo maligna melanoma is the least frequent subtype followed by acral 
lentiginous melanoma, nodular melanoma and superficial spreading melanoma, 
the most frequent subtype [23]. However, this classification has no prognostic 
value or diagnostic relevance [18, 31]. 
 
Table 1: Clinical classification of cutaneous melanoma [23]. 
Subtype Frequency 
Common 
site 
Distinguishing features 
Superficial spreading melanoma 
(SSP) 
70% 
Trunk of men   
Leg of woman      
RGP, 1-5 years 
Nodular melanoma (NM) 10-25% 
Trunk of men   
Leg of woman      
RGP, 6-8 months 
Acral lentiginous melanoma (ALM) 5% 
Palms, soles, 
nails 
Not related to sun damage, all 
races affected, 30-70% in 
dark-skinned individuals 
Lentigo maligna melanoma (LMM) <1% 
Head and 
neck of 
elderly 
Associated with chronic sun 
exposure 
RGP, 3-15 years 
Legend: RGP, radial growth phase. 
 
Melanoma progression was described in the 80’s, in a five steps model known as 
Clark’s model (Fig. 2) [32]. This model comprises: 1) benign proliferation of 
melanocytes along the basal layer of epidermis, called benign nevus or 
melanocytic nevus [33]; 2) dysplastic nevus, with a malignant potential, defined as 
a brownish patch harboring variable pigmentation, asymmetry and/or irregular or 
indistinct borders [26]; 3) melanoma in situ that is a non-tumorigenic lesion related 
to an early radial growth phase (RGP) of melanoma, with an abnormal proliferation 
of melanocytes that grow in an irregular and lateral pattern entirely within and 
limited to the epidermis [34]; 4) locally invasive melanoma that presents vertical 
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growth phase (VGP), which require the acquisition of additional genetic 
abnormalities, with the cells leaving the epithelium of the epidermis and entering in 
the subjacent mesenchymal tissue, such as the dermis or submucosa [34, 35]; 5) 
metastatic melanoma, which is characterized by the spread of malignant 
melanoma cells beyond the local site of the primary tumor, colonizing other 
tissues, such as lymph nodes [34, 36]. Along this melanoma progression model, 
the most critical event is the transition from RGP to VGP, which involves the 
escape from keratinocyte-mediated growth control [37]. Metastases appear latter 
and occur through the lymphatic system, to local lymph nodes. Distant metastases 
involving visceral sites, which occur through systemic dissemination, appear 
afterward, being the most common sites lung, liver, brain, bone, and small 
intestine. The presence of distant metastasis determines the prognosis of 
cutaneous melanoma [38, 39]. 
Melanoma has a relatively good prognosis when diagnosed early at a cutaneous 
localized stage, but patients with distant metastatic disease have a median 
survival of only 8-9 months and less than 10% of 10-year overall survival [35, 40, 
41]. More than 95% of patients with three or more sites of metastatic disease die 
within one year [42]. Fortunately, most cases of cutaneous melanoma are 
diagnosed in an early stage, reaching 98% on 5-year survival rate [43]. Staging of 
cutaneous melanoma is based on the TNM (Tumor Node Metastases) staging 
system developed by the AJCC (American Joint Committee on Cancer) 
(Supplementary table 1, Appendices). Melanoma staging is based on prognostic 
factors such as tumor thickness (Breslow method), mitotic rate, ulceration, number 
of lymph nodes, tumor burden, LDH serum levels and anatomic site of distant 
metastases [35]. 
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Figure 2: Melanoma progression model. There are five stages of histopathologic progression in 
melanocyte transformation from normal skin to metastatic disease. 1) Benign nevus; 2) Dysplastic 
Nevus; 3) Melanoma in situ; 4) Invasive Melanoma and 5) Metastatic Melanoma. Adapted from 
http://www.biochim.ro/ib/projects/melanoma-trp2/background.php. 
 
1.2.4 Genetic and molecular alterations in cutaneous melanoma 
Clinic, epidemiology and more recently genetics, reveal that melanomas are 
heterogeneous tumors, harboring various genetic alterations, developing at 
different body sites, on sun and non sun-exposed skin, suggesting that melanoma 
arises from divergent causal pathways [40]. Deregulation of MAPK and 
PI3K/AKT/mTOR pathways is linked to melanoma development through the 
modulation of cell growth, proliferation and apoptosis [44]. The mitogen-activated 
protein kinase/extracellular-signal-regulated kinase pathway (MAPK) is the most 
frequently and constitutively activated pathway in melanoma [45]. The canonical 
MAPK pathway (RAS–RAF–MEK1/2–ERK1/2) is the best characterized and the 
aberrant activation commonly occurs through gain-of-function mutations in genes 
encoding RAS and RAF family members [46, 47]. BRAFV600 and NRASQ61 
mutations are the most frequently identified mutations in cutaneous melanoma, 
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50% and 25%, respectively, indicating an important role for MAPK pathway 
activation in melanoma development [48-52]. BRAFV600 -induced MAPK signaling 
has been associated with most aspects of human melanoma development and 
progression in the last decades. Several studies show their involvement in many 
tumorigenic processes leading to an increase in cell proliferation, survival, 
hypoxia, invasion, metastization and angiogenesis [53-59]. However, benign 
melanocytic nevi cells frequently express oncogenic BRAFV600, remaining in 
growth-arrest for decades because of oncogene-induced senescence (OIS) [60]. 
Bypass senescence is required for malignant transformation since it provides an 
efficient suppression of cell proliferation and tumorigenesis. One mechanism to 
bypass senescence is through the activation of the PI3K/AKT/mTOR pathway. 
Events like PTEN loss or AKT overexpression, which occur in melanoma and drive 
to PI3K/AKT/mTOR pathway overactivation [61, 62], can overcome this 
senescence and lead to melanoma progression [63]. Studies showed that higher 
mTOR pathway activation was found in cutaneous melanoma and related with 
MAPK pathway BRAF -activation [64]. The presence of both BRAF mutations and 
activation of PI3K/AKT/mTOR pathway simultaneously is associated with 
cutaneous melanoma aggressiveness, worse prognosis and short patient's overall 
and progression-free survival [64]. 
The major driving force behind the initiation and progression of melanoma 
development may be the acquisition of somatic mutations in key regulatory genes 
[65]. The most frequently altered genes in melanoma are BRAF, NRAS (from 
MAPK pathway), AKT, PTEN (from PI3K/AKT/mTOR pathway) KIT, TERT and 
p53 (Table 2) [66, 67]. Other genes as CDKN2A, CDK4, MC1R, MDM-2, ERK, E-
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cadherin and N-cadherin were reported as being altered during melanoma 
progression [67]. 
 
Table 2: Most frequently altered genes in sporadic cutaneous melanoma. 
Genes Frequency Type 
Oncogenes 
BRAF 40 - 70% Mutation 
NRAS 10 - 20% Mutation 
c-KIT 30 - 40% Mutation or amplification 
AKT 60% Amplification or mutation (OE) 
TERT 12 - 71% Mutation 
Tumor Suppressor Genes 
p53 10% Loss or mutation 
PTEN 30 - 50% Deletion, LOH or mutation 
Legend: OE, Overexpression; LOH, Loss of heterozygosity 
 
1.2.5 Cutaneous melanoma therapy 
If detected at an early stage and treated properly, melanoma has a high rate of 
curability. Standard cutaneous melanoma treatment for localized disease consists 
of primary tumor surgical excision followed by adjuvant therapy, such as 
radiotherapy, to avoid recurrence. Until recently, melanomas with deep local 
invasion, or lymph nodes involvement, could only be treated with surgery, 
immunotherapy (interleukin-2 and interferon α-2b), chemotherapy, and/or 
radiotherapy [68]. Most patients suffering from metastatic disease carries a poor 
prognosis, with less than 1 year of median survival, and mortality reaching 90% in 
overall 5-year rate [69]. Over the past decades, efforts were hampered to 
overcame melanoma resistance to therapy and improve overall survival of 
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melanoma patients. Resistance to apoptosis both in vivo and in vitro appears to be 
the major cause of chemotherapy drug resistance in melanoma [70].  
Understanding melanoma genetics, pathogenesis, tumor heterogeneity and the 
complexity of underlying biologic pathways allowed the development of target 
treatment, leading to more durable responses [71-73]. The gene mutations 
referred above are generally exclusive, therefore melanoma can be molecularly 
classified into distinct subtypes, where these alterations can emerge as targets 
and predictive factors for therapy response [39]. Several novel therapeutic 
strategies, such as immuno- and targeted therapies, were approved by FDA (Food 
and Drug Administration) for melanoma treatment (Table 3) [74, 75]. 
Dacarbazine is the only currently chemotherapeutic agent approved by FDA for 
metastatic melanoma treatment, and is associated with modest response rates 
and low effects in overall survival of patients, when administered alone [76, 77]. 
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Table 3: FDA approved therapies for advanced/metastatic melanoma treatment. 
  
Drug Melanoma Stage Purpose 
Mechanism of 
action 
Chemo 
therapy 
dacarbazine 
(DTIC) 
Stage IV melanoma 
Shrink or slow the 
growth of 
melanoma spread 
throughout the 
body 
DTIC is a 
chemotherapy drug 
that interferes with the 
growth of cancer cells. 
Currently, is the only 
FDA approved 
chemotherapy drug for 
the treatment of 
metastatic melanoma 
Im
m
u
n
o
th
e
ra
p
y
 
interleukin-2   
(IL-2) 
Advanced metastatic 
melanoma 
Use body’s 
natural immune 
system to fight 
melanoma 
IL-2 is a cytokine which 
activate the immune 
system (including T cell 
and natural killer cells) 
to kill cancer cells 
high-dose or 
pegylated 
interferon α-2b 
Stage III patients, free 
of disease but with high 
risk of recurrence after 
surgery and Stage IIB 
or Stage IIC patients 
with lesions of Breslow 
thickness > 4mm 
Accelerate the 
immune system in 
order to kill 
melanoma cells 
and prevent 
recurrence after 
surgery 
The main function is 
alert the immune 
system to kill 
melanoma cells. Intron 
A and Sylatron are 
possible 
antiangiogenic, 
blocking tumor growth 
talimogene 
laherparepvec 
(T-Vec)  
Local unresectable 
cutaneous, 
subcutaneous, and 
nodal lesions, recurring 
after initial surgery 
Replicate within 
cancer cells and 
produce an 
immunostimulator
y protein GM-CSF 
(granulocyte-
macrophage 
colony-stimulating 
factor) 
T-Vec is a modified live 
oncolytic herpes virus 
designed to cause cell 
lysis, or death. Disrupts 
the tumor, and release 
tumor-derived 
antigens, which along 
with GM-CSF, may 
promote an anti-tumor 
immune response. It is 
the first FDA approved 
oncolytic virus therapy 
nivolumab 
Unresectable Stage III 
melanoma (cannot be 
completely removed by 
surgery) or Stage IV 
melanoma 
Block PD-1, which 
results in an anti-
tumor immune 
response 
Opdivo is a humanized 
monoclonal antibody  
that blocks the 
interaction between 
PD-1 and its ligands 
PD-L1 and PD-L2, 
releasing PD-1 
pathway-mediated 
inhibition of the 
immune response 
pembrolizumab 
Unresectable Stage III 
melanoma (cannot be 
completely removed by 
surgery) or Stage IV 
melanoma 
Block PD-1, which 
results in an anti-
tumor immune 
response 
Keytruda is a 
humanized monoclonal 
antibody that blocks 
the interaction between 
PD-1 and its ligands 
PD-L1 and PD-L2, 
which restricts the 
body’s immune system 
from attacking 
melanoma cells 
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ipilimumab 
Stage III or Stage IV 
melanoma 
Blocks the activity 
of CTLA-4. 
Restore and 
sustain an active 
immune system 
by supporting the 
activation and 
proliferation of T-
cells 
Yervoy is a human 
monoclonal antibody 
designed to block the 
activity of CTLA-4, a 
protein that normally 
helps to keep the 
immune system cells, 
called T cells, in check. 
When CTLA-4 is 
blocked, T cells are 
active and proliferate in 
order to attack the 
melanoma cells. 
nivolumab and 
ipilimumab 
combination  
Unresectable Stage III 
melanoma (cannot be 
completely removed by 
surgery) or Stage IV 
melanoma 
Block PD-1 and 
CTLA-4, 
respectively 
Opdivo and Yervoy are 
both monoclonal 
antibodies and immune 
checkpoint inhibitors. 
Enhance T cell 
functions greater than 
the effects of either 
antibody alone 
T
a
rg
e
te
d
 T
h
e
ra
p
y
 
trametinib 
Patients with 
BRAFV600 mutation 
and unresectable Stage 
III melanoma or Stage 
IV  
Block MAPK 
pathway and 
inhibit the growth 
of melanoma 
tumors 
Mekinist is a MEK 
inhibitor that blocks the 
activity of MEK 1 and 2 
particulary in metastatic 
melanoma carrying the 
BRAF V600 mutation 
dabrafenib 
Patients with 
BRAFV600 mutation 
and unresectable Stage 
III melanoma or Stage 
IV  
Block MAPK 
pathway and 
inhibit the growth 
of melanoma 
tumors 
Tafinlar is a kinase 
inhibitor that blocks the 
activity of the V600 
mutated form of BRAF 
vemurafenib 
Patients with 
BRAFV600 mutation 
and unresectable Stage 
III melanoma or Stage 
IV  
Block MAPK 
pathway and 
inhibit the growth 
of melanoma 
tumors 
Zelboraf is a kinase 
inhibitor that blocks the 
activity of the V600 
mutated form of BRAF 
cobimetinib and 
vemurafenib 
combination  
Patients with 
BRAFV600 mutation 
and unresectable Stage 
III melanoma or Stage 
IV  
Block MAPK 
pathway and 
inhibit the growth 
of melanoma 
tumors 
Zelboraf is a kinase 
inhibitor that blocks the 
activity of the V600 
mutated form of BRAF 
and Cotellic is an 
inhibitor that blocks the 
activity of MEK 
trametinib and 
dabrafenib 
combination  
Patients with 
BRAFV600 mutation 
and unresectable Stage 
III melanoma or Stage 
IV  
Block MAPK 
pathway and 
inhibit the growth 
of melanoma 
metastases 
Tafinlar and Mekinist 
are inhibitors of the 
mutated forms of BRAF 
and MEK, respectively 
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Since 2002, when Davies et al. reported for the first time a high frequency of 
BRAF point mutations in melanoma and other human cancers, many publications 
establish these BRAF mutations as drivers of oncogenesis and as direct targets 
for therapeutic intervention [78]. Based on BRAF oncogenes, a series of small-
molecule inhibitors have been developed, which target BRAFV600. Following the 
failure of sorafenib, the first RAF-inhibitor actively studied in patients with 
melanoma, more potent and selective inhibitors of BRAF have been developed, 
namely vemurafenib and dabrafenib [79-81]. Vemurafenib and dabrafenib are 
small molecules highly potent and selective ATP-competitive BRAF inhibitors. 
These drugs act by binding to the active site in the kinase domain, in its active 
conformation, blocking the access to ATP. They lead to decreased proliferation 
and increased programmed cell death, through reduction of phosphorylated ERK 
and cyclin D1 [82]. Deactivating BRAFV600 mutant proteins improved progression 
free-survival and overall survival of patients with unresectable stage III or stage IV 
melanoma [83-86]. Because of the potential efficacy towards melanoma, in 2011 
and 2013, vemurafenib (PLX4032) and dabrafenib (GSK2118436), respectively, 
received US Food and Drug Administration (FDA) approval for the treatment of 
patients with unresectable Stage III melanoma or Stage IV melanoma who carry 
the BRAFV600 mutation [86, 87]. Vemurafenib is a potent inhibitor of the kinase 
domain of mutant BRAF that Phase III trials of vemurafenib, targeting mutated 
BRAF, demonstrated effectiveness in metastatic melanoma treatment with 
significantly high response/tumor burden reduction (85%), increase in overall 
survival rate (84%), reduction in risk of death from disease (63%) and a median 
progression-free survival between 6 and 9 months [81, 84, 85]. Nonetheless, 
treatment with BRAF inhibitors is associated with diverse side effects as nausea, 
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fatigue, rash, arthralgia, alopecia, and photosensitivity reaction [88]. Also other 
adverse illnesses can appear, such as hyperkeratosis, verrucous keratosis, 
papillary lesions, keratoacanthomas and/or squamous cell carcinoma [89-91]. The 
MAPK-pathway is part of a complex network containing scaffold proteins and 
feedback loops. Therefore, another obstacle for the use of BRAF inhibitors in 
metastatic melanoma treatment is the rapidly acquisition of secondary resistance, 
typically in 5–7 months. Several MAPK-dependent and -independent resistance 
mechanisms that allow cells to bypass BRAF inhibition, by re-activating MAPK 
pathway and/or activating other signaling pathways, have been described [92]. 
NRAS oncogenic mutations, upregulation of CRAF proteins, activating mutations 
of MEK1/2, amplification of MAP3K8, or loss of the RAS suppressor NF1, are 
some of the resistance mechanisms that can re-activate MAPK pathway, by re-
establishing MEK activity and hence reactivation of ERK [93-99]. Increased 
expression of eIF4F complex, EGF receptor and pro-survival factors as anti-
apoptotic Bcl-2 proteins may also lead to the reactivation of MAPK pathway [100-
102]. Overexpression of the mutant BRAF protein itself confers resistance to 
BRAF inhibitors and also, alternative splicing of BRAFV600 leads to the formation of 
BRAF truncations, through RAF dimerization that activates MEK, resulting in 
acquired resistance to selective BRAF inhibitors [103, 104]. Apart from cell-
autonomous resistance, the tumor-stroma can also confer resistance to BRAF 
inhibitors. Stromal fibroblasts can secrete HGF that re-activate ERK through 
cMET/RAS/CRAF- signaling [105]. MAP kinase pathway-independent 
mechanisms of resistance involve alterations of the activation in receptors of 
tyrosine kinases (RTKs), such as overexpression or over-activation of PDGFR-β 
(platelet-derived growth factor receptor beta) and IGF1R (insulin growth factor 1- 
DCA as a possible therapy for cutaneous melanoma in combination with approved therapeutics 
 
14 
 
receptor), which leads to the induction of oncogenes, by upregulation of the 
PI3K/AKT/mTOR signaling pathway. Also, acquired loss of tumor suppressor 
PTEN and amplification or point mutations on AKT, contribute for PI3K pathway 
activation, another potential driver of resistance [94, 106-108]. 
Other small molecule used in target therapy is trametinib, a MEK1/2 inhibitor that 
blocks MAPK pathway in order to stop the growth of melanoma tumors, showing 
improved progression free-survival over dacarbazine [109]. Combined therapies 
with these promising drugs as trametinib + dabrafenib and cobimetinib + 
vemurafenib were FDA-approved in 2014 and 2015, respectively [74, 110]. As 
response rates increased with these therapies, it becomes evident that 
combination therapies, targeting several signaling pathways simultaneously, might 
be an efficient therapeutic strategy to treat melanoma patients. Other signal 
transduction drugs as PI3K, AKT and mTOR inhibitors are being evaluated in 
combination with BRAF and MEK inhibitors [111]. 
Another available therapy to treat melanoma is to detect and destroy tumor cells, 
by stimulating the immune system of the patients. High-dose interferon α-2b or 
pegylated interferon α-2b are cytokines used as immunotherapies that improve 
recurrence-free survival but not overall survival [112, 113]. Interleukin-2 is also an 
immunotherapeutic agent used in stage IV metastatic melanoma patients that 
showed disease-free and overall survival increase, but lower effectiveness [114]. 
As interferon and interleukin treatment trigged severe side effects in patients, 
monoclonal antibodies targeting immune checkpoint proteins have been approved 
recently. Ipilimumab, an anti-CTLA4 antibody, was the first revealing improvement 
in progression-free and overall survival in patients with unresectable advanced 
melanoma [115, 116]. Other promising monoclonal antibodies include those 
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against programmed death receptor-1 (PD-1), pembrolizumab and nivolumab, 
better tolerate and efficient when compared with ipilimumab [117-119]. The 
combination of CTLA-4 and PD-1 antibodies (ipilimumab + nivolumab) showed 
significant increase in progression-free survival, in comparison to these as single 
agent [120, 121]. Other immunotherapeutic strategies for advanced melanoma are 
being investigated, such as adoptative T-cell therapy (ACT) and melanoma 
vaccines, based on dendritic cells and training to recognize melanoma-specific 
antigens [122, 123]. Nowadays, available therapies still have limitations in the 
treatment of melanoma patients and mortality remains high [109, 124]. 
 
1.3 mTOR pathway activation in cutaneous melanoma 
mTOR (mammalian target of rapamycin), a downstream effector of the frequently 
deregulated pathway in melanoma PI3K/AKT/mTOR pathway, is a conserved 
serine/threonine kinase that regulates survival, growth, proliferation, metabolism 
and motility, in response to growth factors, energy, nutrient and O2 levels [125-
127]. mTOR forms two functionally distinct multiprotein complexes, mTORC1 and 
mTORC2 [128]. mTOR complexes differ in their sensitivity to rapamycin (mTOR 
inhibitor); mTORC1 is sensitive to rapamycin, whereas mTORC2 is considered 
resistant [129, 130]. mTORC1 is a major regulator of protein synthesis and 
ribosome biogenesis; is activated by the PI3K/AKT pathway, mostly through 
phosphorylated AKT (on Thr308), that unleashes the signaling cascade, blocking 
the formation of the TSC1/TSC2 inhibitor complex [131-133]. It is also involved in 
the regulation of other important proteins such as HIF1-α [134]. Two most well-
known downstream effectors of mTORC1 are S6K and 4EBP1; its phosphorylation 
status is commonly used to access the mTOR complex 1 activity [135]. The 
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serine/threonine kinase p70S6K1 (S6K1) is activated by phosphorylation at 
Thr389 by mTORC1; once activated, S6K1 phosphorylates S6 (40S ribosomal 
protein S6) enhancing the translation of mRNAs from ribosomal proteins, 
elongation factors, and insulin growth factor [136, 137]. The other well-
characterized mTORC1 target 4EBP1, when unphosphorylated, forms a complex 
with the eukaryotic translation initiation factor 4E (eIF4E), binding and inactivating 
its functions [138]. Phosphorylation by mTORC1 at multiple serine/threonine sites 
of 4EBP1, allows its dissociation from eIF4E, relieving the inhibitory effect on 
eIF4E-dependent translation initiation. Once free and active, eIF4E enables the 
translation of cap-dependent proteins and mRNAs of its downstream target genes 
required for G1-to-S phase transition such as c-myc, ornithine decarboxylase and 
cyclin D1 [137, 139, 140]. mTORC2 is resistant to rapamycin; however long-term 
treatment with this agent is capable to disassemble mTORC2 complex, by 
sequestering newly synthetized mTOR molecules, blocking its functions [141]. 
Growth factors are the major activators of mTORC2. Once activated, this complex 
phosphorylates PKC-α, AKT (on Ser473) and the focal adhesion-associated 
protein, paxillin. mTORC2 also interferes with small GTPases, such as Rac and 
Rho, trough regulation of their activity on cell survival, migration and actin 
cytoskeleton [130, 141, 142]. Given the key role of mTOR in cell growth and 
metabolism, and its involvement in cancer trough oncogene stimulation or loss of 
tumor suppressors that enables cell growth, angiogenesis and metastasis, it 
become a desirable therapeutic target [143]. Anti-cancer therapies targeting 
mTOR, namely the fungal macrolide rapamycin (naturally mTOR inhibitor) and its 
analogues (rapalogues) were developed. mTOR inhibitors (mTORi) can be divided 
in two groups: rapamycin and rapalogues, and the small molecules that are mTOR 
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kinase inhibitors. Rapamycin, an allosteric inhibitor of mTOR, was isolated from 
the bacterium Streptomyces hygroscopicus, which was found in a soil sample from 
Easter Island [144, 145]. First fungicide and subsequently potent 
immunosuppressive and anti-tumor properties were assigned to rapamycin effect 
[146, 147]. Rapamycin (rapamune, sirolimus) was the first mTOR inhibitor 
approved by FDA in 1999, as an immunosuppressant drug for prophylaxis of 
organ rejection in kidney transplant recipients [148, 149]. In recent years, interest 
has focused on its potential as an anticancer drug. Several studies, performed in 
cell lines derived from different tumors, reveal that rapamycin promotes direct anti-
tumor effects, such as cell growth arrest [134]. Accumulation of cells in G1-phase, 
after rapamycin treatment, is consistent with the fact that the drug inhibits 
ribosome biogenesis and global translation, in part by blocking S6K1 and 4EBP1 
phosphorylation [131, 134]. Moreover, rapamycin can also inhibit endothelial cell 
proliferation, HIF1 and VEGF expression, angiogenesis, and vascular permeability 
[150, 151]. Pharmacological molecules derived from rapamycin (rapalogues), with 
better water solubility profiles and efficacy, have been developed, such as 
temsirolimus, everolimus and deforolimus [152]. These rapamycin analogues are 
cell-type specific mTORC1 and partial mTORC2 inhibitors, and act forming a 
complex with the intracellular receptor FKBP12 that bind to mTOR and inhibit the 
downstream signaling [153]. Rapamycin and rapalogues are already been used for 
the treatment of various dermatologic conditions and rapalogues are in clinical 
trials for cancer treatment [154, 155]. Moreover, previous studies showed that they 
may achieve a high response rate of treatment and have an antiproliferative 
activity on several types of cancer [156, 157]. However, the performance of 
rapamycin and its analogues has been undistinguished and, despite isolated 
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successes, the antiproliferative effect was variable among cancer types. It is well 
known that rapamycin and its rapalogues mediate their effects by inhibiting 
mTORC1, with limited or no effect on mTORC2 activity, being this the major 
limitation of mTOR inhibitors [152]. Therefore, a new generation of small molecule 
inhibitors was developed. These molecules are ATP-competitive inhibitors that 
directly target the mTOR catalytic site. As they inhibit mTORC1 activity, 
consequently block the phosphorylation of S6K1, and as they inhibit mTORC2, 
they block AKT phosphorylation. Higher effects on blocking cell proliferation and 
protein translation are assigned to these selective inhibitors, when compared with 
rapamycin and analogues [158, 159]. One rapalogue, everolimus, also known as 
RAD001, was approved by FDA as immunosuppressant for solid-organ 
transplantation and allograft rejection [160]. Everolimus blocks the cytokine-driven 
activation responses of T- and B-cells, preventing their proliferation and 
differentiation. It was already approved as treatment for advanced renal cell 
carcinoma, tuberous sclerosis SEGA tumors, pancreatic neuroendocrine tumors, 
tuberous sclerosis angiomyolipoma and, advanced breast cancer [161]. Phase II 
studies in Hodgkin and non-Hodgkin’s lymphoma also reveal a good response rate 
(47% and 30%, respectively) with everolimus treatment [162, 163]. Reported 
effects of everolimus in some human tumors and cancer cell lines include 
inhibition of cell proliferation, migration, invasion and angiogenesis, as well as 
promotion of apoptosis [164]. Despite everolimus antiproliferative effect in cancer 
cell lines and animal models, the specific inhibition of mTORC1 with this agent 
might induce upstream receptor tyrosine kinase signaling and AKT upregulation, 
leading to the attenuation of its therapeutic effects [165]. Recognition that 
rapamycin and rapalogues have limited substrate-specific efficacy and activate 
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several negative oncogenic feedback loops, has fueled the development of new 
strategies to address these limitations. Dual PI3K-mTOR inhibitors are being 
developed to target both mTOR function and other PI3K signaling activated 
molecules, in order to improve the anti-tumor activity [166-168]. Although not yet 
used in melanoma treatment, higher sensitivity to everolimus was described in 
cutaneous melanoma cell lines harboring BRAFV600 mutation [169]. Also, a recent 
phase II study reported that treatment of metastatic melanoma with a combination 
of bevacizumab (angiogenesis/VEGF inhibitor) and everolimus, was well tolerated 
and moderately efficacious [170]. Nevertheless, for most tumor types, mTOR 
inhibitors have been more associated with disease stabilization rather than tumor 
regression. Therefore, several studies combining mTOR inhibitors with other 
therapies, as conventional chemotherapy agents, EGFR or HER-2 inhibitors, 
hormonal therapy, HIF1-α and VEGF inhibitors, and MAPK pathway inhibitors 
were performed, showing a more cytotoxic response and higher tumor regression 
[67, 134]. In melanoma, clinical trials with mTOR inhibitors alone yield high toxicity 
for patients and minor response rates [171]. Rapamycin has shown effectiveness 
on increasing apoptosis and chemosensitivity, and the anti-tumor effect seems to 
be enhanced when combined with inhibitors of MAPK and PI3K pathways [172-
175]. 
 
1.4 Metabolism modulation in cutaneous melanoma 
As other cancer cells, melanoma cells exhibit the Warburg effect, a shift from 
oxidative phosphorylation to glycolysis, which increase glucose consumption and 
lactate production, comparing to normal melanocytes [176]. The metabolic rewiring 
observed in cancer cells plays a role on driving development and progression, 
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promoting survival, proliferation, and long-term maintenance [177, 178]. Contrary 
to normal cells, cancer cells can reprogram their metabolism and energy 
production. They limit their metabolism to glycolysis, even in the presence of 
oxygen, leading to a process called ‘aerobic glycolysis’ also known as Warburg 
effect [179, 180]. Aerobic glycolysis is an inefficient way to obtain ATP compared 
with mitochondrial respiration; however, the rate of glucose metabolism through 
aerobic glycolysis is higher than the complete oxidation of glucose in the 
mitochondria [181, 182]. Therefore, increased glucose consumption is used as a 
carbon source for anabolic processes to generate nucleotides, lipids, and proteins, 
essential for cells to proliferate [183-185]. Many tumors with high rate of cell 
proliferation have a hypoxic environment with low-oxygen availability, mainly 
because the formation of new blood vessels does not supply enough oxygen. The 
metabolic adaptation to hypoxia involves induction of metabolic genes that 
increase glycolytic flux and is achieved through hypoxia-inducible factor (HIF1-α). 
HIF1-α seems to be constitutive activated in some tumors, where it induces 
glycolysis and inhibits mitochondrial biogenesis [186]. As skin is a moderate 
hypoxic environment, cutaneous melanoma present overexpression of HIF1-α, 
perhaps due to indirect stimulation of expression by reactive oxygen species 
(ROS), derived from melanin production [187, 188]. UVA-irradiation, partially 
through ROS, leads to enhancement of the Warburg effect in melanoma cells and 
increase the invasive potential [189]. Furthermore, the Warburg effect enables 
cancer cells to avoid excess ROS generation from mitochondrial respiration, by 
limiting the pyruvate flux into mitochondrial oxidative metabolism, and thus gain 
increased resistance to cell death and survival advantage for metastization [190]. 
Understanding tumor metabolism reprogramming, reversibility of the Warburg 
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effect, and knowledge of mitochondrial oxidative metabolism as an important 
suppressor of metastasis, allows the opening of a therapeutic window to generate 
new anti-tumor drugs that target altered metabolism in cancer cells and may 
prevent tumor metastization [191, 192]. Dichloroacetate (DCA) is an old drug, 
already used in humans for more than 30 years, in the treatment of some 
congenital mitochondrial diseases that present deficiencies of PDH or other 
mitochondrial enzymes, like severe lactic acidosis [193]. It is a small-molecule 
pyruvate mimetic compound included in a new class of “metabolic modulators” that 
target and switch cancer cells metabolism toward a more normal phenotype [194-
196]. Pro-apoptotic and anti-proliferative effects were assigned to DCA in a large 
variety of cancers, such as prostate, colon, gastric and endometrial cancer, 
glioblastoma, neuroblastoma, T-cell lymphoma, non-Hodgkin’s lymphoma, 
fibrosarcoma, and metastatic breast cancer [197, 198]. In cutaneous melanoma, 
DCA seems to be a possible therapeutic candidate showing a rewiring of 
metabolism, downregulation of proliferation, increase apoptosis and decrease 
activation of the mTOR pathway [199]. DCA acts by inhibiting pyruvate 
dehydrogenase kinase (PDK). Contrary to healthy tissues, where PDK activity is 
low, in cancer cells there is a high level of PDK activity, mostly due to the 
activation by HIF1-α, that is overexpressed [200]. PDK is one of the elements that 
compose the mitochondrial pyruvate dehydrogenase complex (PDC), along with 
pyruvate dehydrogenase enzyme (PDH) and pyruvate dehydrogenase phosphate 
(PDP). Once upregulated, PDK phosphorylates and inhibits PDH, at E1-α subunit, 
leading to an increase glycolytic phenotype over glucose oxidation [201]. DCA 
blocks PDK activity, allowing PDH dephosphorylation and activation (Fig. 3). 
Thereby, a higher amount of pyruvate enters in the mitochondria and is catalyzed 
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by oxidative decarboxylation into acetyl-CoA and then used in tricarboxylic acid 
cycle (TCA) [201]. 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic representation of dichloroacetate (DCA) interactions with pyruvate 
dehydrogenase kinase (PDK) and HIF1-α. DCA inhibits PDK that can be upregulated by HIF1-α, 
which in turn can be activated by mTOR and BRAF. Adapted from Populo et al. [199]. 
 
Thus, DCA promotes the conversion of the glycolytic phenotype into an oxidative 
phenotype [194]. DCA also inhibits HIF1-α, which is involved in the enhancement 
of the glycolytic phenotype and is overexpressed in melanoma [187, 202, 203]. 
Studies performed in non-small-cell lung, glioblastoma and breast cancer cells 
reported that DCA also promotes glucose oxidation, depolarization of 
mitochondrial membranes, induces apoptosis, decreases cell growth, and 
increases ROS production [204]. Therefore, DCA is a promising drug for cancer 
therapy, particularly in melanoma, alone or in combination with already approved 
therapies. 
 
DCA as a possible therapy for cutaneous melanoma in combination with approved therapeutics 
 
23 
 
2 Aims 
Recently approved therapies for cutaneous melanoma targeting MAPK pathway 
have limitations, such as fast acquirement of resistance. Therefore, the 
development of new and efficient therapies to treat and improve survival of 
melanoma patients is necessary. Cutaneous melanoma cells display 
overactivation of the two interconnected MAPK and PI3K/AKT/mTOR pathways 
and evidence the presence of the Warburg effect. MAPK inhibitors improve overall 
and progression free-disease survival of melanoma patients. PI3K, specifically 
mTOR inhibitors, already prove to have anti-tumor properties. DCA that targets 
metabolism and promotes apoptosis, may reverse the metabolic switch and 
promote tumor regression. 
The major goal of this study was to determine if DCA, in combination with mTOR 
inhibitors or BRAF inhibitors, is a suitable drug to use as therapy for melanoma 
patients. We hypothesize that reverting melanoma cell metabolism (from glycolysis 
to oxidative phosphorylation), may have therapeutic benefits in combination with 
already approved therapies. To test this hypothesis we analyzed the sensitivity of 
melanoma cell lines to combined therapy of DCA with everolimus (mTOR inhibitor) 
and with vemurafenib (BRAF inhibitor), and checked if this combination could be 
addictive or synergistic and also checked if DCA could overcome resistance to the 
treatment with vemurafenib of melanoma cells. Moreover, as mTOR and MAPK 
(BRAF –activated) pathways are interconnected in cutaneous melanoma, another 
goal for this study was to determine if the combined therapy of mTOR and BRAF 
inhibitors may have an additive and improved effect on melanoma therapy. 
DCA as a possible therapy for cutaneous melanoma in combination with approved therapeutics 
 
24 
 
 
DCA as a possible therapy for cutaneous melanoma in combination with approved therapeutics 
 
25 
 
3 Material and Methods 
3.1 Cell lines and culture conditions 
Three different melanoma cell lines were used in this study: A375 (BRAFV600E), 
Mewo (BRAF-wildtype) and ED013R2 (BRAFV600E; vemurafenib resistant). A375 
cell line was provided by Dr. Madalena Pinto, from CEQUIMED, Faculty of 
Pharmacy, University of Porto, Portugal. Mewo cell line was provided by Dr. Marc 
Mareel, from the Department of Radiotherapy and Nuclear Medicine, Ghent 
University Hospital, Belgium. Vemurafenib-resistant cell line (ED-013R2) was 
provided by Prof. Per Guldberg, from the Danish Cancer Society Research Center, 
Copenhagen, Denmark. This last cell line was generated from a parental 
BRAFV600E cell line (ED-013) by exposing the cells to increasing concentrations of 
vemurafenib and were considered resistant when they could be continuously 
propagated at a concentration of vemurafenib above the IC50 [205]. A375 was 
maintained in RPMI medium (Gibco/BRL – Invitrogen) and Mewo in DMEM 
medium (Gibco/BRL – Invitrogen), both supplemented with 10% of fetal bovine 
serum, 100U/mL Penicillin and 100ug/mL Streptomycin. The ED013R2 
vemurafenib-resistant line was maintained in RPMI medium (Gibco/BRL – 
Invitrogen), supplemented as previous described mediums, plus 1µM of 
vemurafenib. Cell lines were maintained at 37°C, in a humidified atmosphere (5% 
CO2) and cultured as a monolayer. 
 
3.2 Treatment of melanoma cell lines with DCA, RAD001 and vemurafenib 
DCA (Sodium dichloroacetate, Sigma-Aldrich, St. Louis, MO, EUA) was dissolved 
in dH2O and filtered. RAD001 (everolimus, Novartis Pharma AG, Basel, 
Switzerland) and vemurafenib (Absource Diagnostics GmbH, München, 
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Deutschland) were dissolved in DMSO. All treatments were added to the culture 
medium and used for 48 and 72h treatment. Melanoma cells incubated with 
culture medium and culture medium supplemented with dH2O and DMSO served 
as control. 
 
3.3 Cell viability assay 
The effect of DCA, RAD001 and vemurafenib in melanoma cell lines viability was 
analyzed by Presto Blue (PB) assay. Cells were seeded in 96-well plates at a 
density of 7x103 (A375), 9x103 (Mewo) and 10x103 (ED013R2) in 200μl medium. 
After 24h, the medium was replaced by a medium containing different treatment 
concentrations and combinations. For DCA, the concentration of 35mM previously 
established was used [199]. For vemurafenib alone, concentrations of 10, 50, 100, 
1000, 2500, 5000nM were used in A375 and Mewo cell lines and, 1, 2.5, 4, 5, 6, 
7.5, 10µM to ED013R2 resistant cell line. For DCA plus RAD001, the 
concentrations of 35mM of DCA and 5, 10, 15 and 20nM of RAD001 were used as 
already reported or as recommended by the manufacture [169, 199]. For DCA plus 
vemurafenib, 35mM of DCA was used and variable concentrations of vemurafenib 
were used according with the cell line (44, 88, 132, 175nM for A375, 1.25, 2.5, 
3.75, 5µM for Mewo and 1, 2.5, 4, 5, 6, 7.5, 10µM for ED013R2). For RAD001 plus 
vemurafenib, 20nM of RAD001 was used as recommended by the manufacture, 
and vemurafenib concentrations were variable, depending on the cell line, as 
described above. Cells were incubated for 48 and 72h, washed with PBS (pH 7.4) 
and assayed for cell growth using PB according to the manufacturer’s instructions. 
During incubation with the cells, PB reagent is modified by the reducing 
environment of the viable cells and becomes highly fluorescent. Fluorescence was 
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measured using a microplate reader (Synergy HT Multi-Mode Microplate Reader, 
BioTek Instruments Inc., Winooski, VT, USA) at excitation and emission 
wavelengths of 560 and 590nm, respectively. The absorbance of the wells 
containing culture medium was used as control, as well as medium with drug 
solvents (dH2O and different DMSO concentrations) and each experimental 
condition was evaluated with triplicates and repeated three times. By comparing 
the measured fluorescence/absorbance of the wells containing treated cells with 
the measurements of the wells containing untreated cells, it was possible to 
generate dose response profiles and determine the IC50 (the concentration that 
inhibits cell survival in 50%) values for vemurafenib, using GraphPadPrism5.0 
(GraphPad Software, Inc., La Jolla, CA). 
 
3.4 Cell count assay 
Cells were plated in 6-well plates at a final density of 1.5×105 cells/well for A375 
and ED013R2 cell lines, and 2×105 cells/well for Mewo cell line; and incubated at 
37°C for 24h. Cells were then treated with 35mM DCA, 10nM and 20nM RAD001, 
vemurafenib (88 and 175nM to A375; 2.5 and 5µM to Mewo; 5 and 10µM to 
ED013R2) and drug combinations of DCA + RAD001, DCA + vemurafenib, 
RAD001 + vemurafenib with the concentrations described above. Following 72 
hours of treatment, cells were collected, diluted 1:200, and the absolute cell count 
was performed using a Z2 Coulter particle counter (Beckman Coulter, Brea, CA). 
Each experimental condition was evaluated in triplicate and repeated three times. 
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3.5 Cell cycle and apoptosis analysis 
For cell cycle profile and apoptosis analysis, melanoma cells were plated in 6-well 
plates at a final density of 1.5×105 cells/well for A375 and ED013R2 cell lines, and 
2×105 cells/well for Mewo cell line; and incubated at 37°C for 24h. Cells were then 
treated with 35mM DCA, 10nM and 20nM RAD001, vemurafenib (88 and 175nM 
to A375; 2.5 and 5µM to Mewo; 5 and 10µM to ED013R2) and drug combinations 
of DCA + RAD001, DCA + vemurafenib, RAD001 + vemurafenib with 
concentrations described above for 72h of treatment. For cell cycle analysis, cells 
were harvested and fixed overnight in ice-cold 70% ethanol. Afterwards, cells were 
resuspended in PBS with 0.1mg/mL RNase A and 5μg/mL propidium iodide, 
before analysis. For apoptosis measurements, cells were harvested and the levels 
of apoptosis were analyzed by flow cytometry using the Annexin-V FITC Apoptosis 
Kit (Clontech Laboratories, Inc., Saint-Germain-en-Laye, France) according to the 
manufacturer’s instructions. Flow cytometry analysis of cellular DNA content and 
phosphatidylserine externalization were performed with a flow cytometer (BD 
Accuri C6), plotting at least 20000 events per sample. The data was analyzed 
using the FlowJo 7.6.5 software (Tree Star, Inc., Ashland, USA). Each experiment 
was evaluated in triplicate and repeated three times. 
 
3.6 Western blot analysis and antibodies 
Cells were lysed for 15min at 4ºC using RIPA buffer (1% NP-40 in 150mM NaCl, 
50mM Tris (pH 7.5), 2mM EDTA) supplemented with protease (Roche Applied 
Science, Penzberg, Germany) and phosphatase inhibitors (Sigma-Aldrich). 
Proteins were quantified using a modified Bradford assay (Bio-Rad). Protein 
samples (50µg) were denatured for 5min at 95ºC, separated in 10% SDS/PAGE 
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gels and then electrotransferred onto a nitrocellulose membrane (GE Healthcare, 
Piscataway, USA) for 2h at 100V on ice. Membranes were blocked for 1h at room 
temperature in phosphate buffered saline (PBS) containing 0.5% Tween-20 and 
5% low-fat dry milk or 4% bovine serum albumin (depending on the dilution of the 
primary antibodies). In order to access the effects of DCA, RAD001 and 
vemurafenib treatment on downstream effectors, the following primary antibodies 
were used: PDH, phospho-PDH Ser293 (1:2000, Abcam); S6, phospho-S6 
Ser235/236, ERK 1/2, phospho-ERK1/2 Thr202/Tyr204, AKT (pan), phospho-AKT 
Ser473, mTOR, phospho-mTOR Ser2448, HIF1-alpha, (all 1:1000; Cell Signaling 
Technology), and BRAF (1:500; Santa Cruz Biotechnology), incubated overnight 
at 4ºC. Secondary antibodies were conjugated with peroxidase (Santa Cruz 
Biotechnology); protein bands were detected by chemiluminescense (ECL 
detection solution) and visualized by X-ray film exposure (GE Healthcare). 
Membranes were re-stained with a goat polyclonal anti-actin (1:2000; Santa Cruz 
Biotechnology) antibody for loading protein control. All experiments and 
quantifications (using Bio-Rad Quantity One 1-D Analysis software (4.6.6 version)) 
were performed in triplicate. 
 
3.7 Wound healing assay 
Migration of the cells was assessed through their ability to close an artificially 
created gap (wound) in the cell growth area. Cells (A375 and Mewo) were seeded 
in high density (depending on cell line) to reach confluence and predicting motility 
in 6-well plates with 2ml appropriate media per well and grown for 24h. Then, the 
media was replaced and the treatment conditions referred above were added. 
Cells were incubated for more 24h. In the third day the medium was removed, a 
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10-μl pipette tip was used to create a ‘scratch’ in the growth area and the same 
medium was reloaded. Cells were placed under a Leica DMI 2000 time-lapse 
microscope (Leica Microsystems, Wetzlar, Germany) and images were recorded 
since 48h until 72h post treatment. Migration was defined as the capacity of the 
cells to migrate into the wound and measured as the percentage of wound 
coverage through time. Images were automatically collected in each field every 
10min using LAS AF software (Leica Microsystems) and further processed using 
Fiji software. 
 
3.8 Motility assay 
For motility assays, cells (A375 and Mewo) were plated in low density (depending 
on the cell line) in a 1µ-slide 4-wellph+ ibiTreat (ibidi GmbH, Martinsried, Germany). 
After seeding for 24h, the medium was replaced and the treatment conditions were 
added. After another 24h, cells were monitored until 72h post treatment, using a 
Leica DMI 2000 time-lapse microscope (Leica Microsystems, Wetzlar, Germany). 
The movement covered by a single cell was quantified only if the cell was 
individualized, remained in the field and did not enter in division or apoptosis. 
Images were collected similarly to wound healing assay. 
 
3.9 Statistical analysis 
Statistical analyses were performed using STAT VIEW-J 5.0 (SAS Institute, Inc., 
Cary, NC). The data from the cell lines experiments was analyzed by the two-
tailed unpaired Student’s t-test. A p value ≤0.05 was considered statistically 
significant. 
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4 Results 
4.1 Effects of DCA, RAD001 and vemurafenib treatment in melanoma cell 
lines viability 
A375, Mewo and ED013R2 melanoma cell lines were exposed to different 
concentrations of DCA, RAD001 and vemurafenib, alone and in combination, to 
establish the effect on cell viability. IC50 of DCA was previously determined as 
35mM for A375 and Mewo cell lines [199]. For RAD001, 20nM were used as 
recommended by the manufacture. 
 
4.1.1 IC50 of vemurafenib in melanoma cell lines 
Increasing concentrations of vemurafenib were used to determine the IC50 in the 
three cell lines after 48h and 72h of treatment (Fig. 4A). Vemurafenib reduced 
viability of A375 and Mewo cell lines in a dose-dependent manner after 48h and a 
higher decrease of the cell viability was observed after 72h treatment. A375 was 
the cell line more sensitive to vemurafenib. After 48h of treatment, a significant 
effect of vemurafenib on A375 cell viability was firstly observed after treatment with 
10nM (86.1±9.3%; p=0.05) (Fig. 4B), in Mewo cell line with 100nM of vemurafenib 
(80.0±13.2%; p=0.04) (Fig. 4C) and in ED013R2 cell line, a similar effect was 
achieved after treatment with 1000nM (68.0±3.5%; p<0.01) (Fig. 4D). The IC50 
values were estimated as 173±3.3nM for A375 (Fig. 4B) and 4990±8.3nM for 
Mewo cell line (Fig. 4C), after 48h of vemurafenib treatment. The IC50 was not 
reached for ED013R2 vemurafenib resistant cell line (Fig. 4D). 
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Figure 4: A) Graphic representation of the percentage of viable cells of A375, Mewo and ED013R2 
melanoma cell lines treated with various concentrations of vemurafenib for 48 and 72h, determined 
by Presto Blue assay. The black line marks the IC50 values obtained that were estimated as 
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173±3.3nM for A375 and 4990±8.3nM for Mewo, after 48h of vemurafenib treatment. In ED013R2 
cell line, growth inhibition was observed after 48h of vemurafenib treatment, although it did not 
reach an IC50 value. B, C and D) Column graphic representation of the percentage of viable cells of 
A375 (B), Mewo (C) and ED013R2 (D) melanoma cell lines treated with various concentrations of 
vemurafenib for 48 and 72h. The data are presented as mean±SD. * refers to significant (p≤0.05) 
difference when comparing cells treated with vemurafenib for 48 and 72h to non-treated cells. 
 
4.1.2 Effects of combined therapies in A375 cell line viability 
After 48h of treatment, A375 cell line showed to be sensitive to 35mM DCA 
treatment, with significantly lower percentage of viable cells compared with the 
control (28.5±4.5%; p<0.01) (Fig. 5A). Treatment with 5, 10, 15 and 20nM of 
RAD001 alone achieved a significant decrease on cell viability compared with the 
control (85.3±3.5%; p<0.01, 78.1±10.5%; p=0.02, 68.5±18.1%; p=0.03 and, 
73.0±11.0%; p<0.01, respectively), after 48h of treatment. Although the decrease 
of viability after RAD001 treatment was dose-dependent, it did not reach 
significance between the different concentrations of the drug. Generally, combined 
therapies seem to increase significantly the sensitivity of A375 cell line, showing a 
decrease on cell viability compared with single therapies. Combined therapy of 
DCA 35mM and increasing concentrations of RAD001 (5, 10, 15 and 20nM) 
progressively decrease cell viability compared with the control (26.1±5.1, 
21.5±5.3%, 19.5±2.4% and 18.2±0.4%, respectively; p<0.01) (Fig. 5A). Comparing 
with treatment with RAD001 5, 10, 15 and 20nM alone, these combinations with 
DCA 35mM reached significantly lower cell viability (p<0.01).  
The same trend was observed in cells treated with combined therapy of DCA 
35mM and vemurafenib 44, 88, 132 and 175nM compared with the control 
(33.9±7.3, 27.5±7.1%, 24.7±10.5% and 21.3±3.9%, respectively; p<0.01), and also 
compared with the treatment with vemurafenib alone (p<0.01), after 48h of 
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treatment. Treatment with RAD001 20nM combined with vemurafenib 44, 88, 132 
and 175nM also decrease significantly the percentage of viable cells compared 
with the control (65.9±1.3, 56.0±1.2%, 40.1±2.2% and 34.0±3.1%, respectively; 
p<0.01), although when compared with vemurafenib 44, 88, 132 and 175nM 
combined with DCA 35mM treatments, the decreased in cell viability was 
significantly smaller (p<0.01), after 48h of treatment. In A375 cell line, lower 
percentage of cell viability were achieved after 72h of treatments, generally with 
the same trends observed after 48h of treatments (Fig. 5A). 
 
4.1.3 Effects of combined therapies in Mewo cell line viability 
In Mewo cell line, after 48h of treatment with 35mM DCA alone, a significant 
decrease of cell viability was achieved compared to the control (57.8±2.7%; 
p<0.01) (Fig. 5B). Mewo cell line treated with RAD001 5, 10, 15 and 20nM alone 
for 48h, achieved a significant decrease on cell viability compared to the control 
(84.6±6.3%; p=0.01, 82.2±6.3%; p<0.01, 79.7±4.0%; p<0.01 and 73.1±18.2; 
p=0.05, respectively), again with non-significant alterations between the different 
RAD001 concentrations, although a tendency for a dose-dependent decrease of 
viability was observed. Combined treatment of DCA 35mM with RAD001 (5, 10, 15 
and 20nM) significantly diminish the cell viability rates of Mewo cell line (43.1±4.7, 
42.9±6.4%, 41.2±1.9% and 39.7±2.2%, respectively), in comparison with the 
control (p<0.01), and with treatments with RAD001 concentration alone (p<0.01 for 
all, except p=0.02 for DCA 35mM plus RAD001 20nM compared with RAD001 
20nM alone). Treatment of Mewo cell line with combined therapies of DCA 35mM 
plus vemurafenib 1.25, 2.5, 3.75 and 5µM, achieved significant low percentage of 
cell viability compared to the control (48.4±5.5, 33.9±1.8%, 29.2±1.9% and 
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27.1±1.1%, respectively; p<0.01). Treatment with RAD001 20nM combined with 
vemurafenib 1.25, 2.5, 3.75 and 5µM also decrease significantly the percentage of 
viable cells (33.5±3.3, 21.0±0.8%, 19.7±1.9% and 20.6±1.5%, respectively) 
compared to the control (p<0.01) and also compared with vemurafenib 1.25, 2.5, 
3.75 and 5µM combined with DCA 35mM treatments (p<0.01 for all, except p=0.02 
for RAD001 20nM plus vemurafenib 1.25 compared with DCA 35mM plus 
vemurafenib1.25), after 48h of treatment. In Mewo cell line, lower percentages of 
cell viability were observed after 72h of each treatment (Fig. 5B). 
 
4.1.4 Effects of combined therapies in ED013R2 cell line viability 
Treatment of ED013R2 cell line with 35mM of DCA, for 48h, lead to a significant 
decrease on the percentage of viable cells, compared to the control (20.5±5.4%; 
p<0.01) (Fig. 5C). ED013R2 cell line treated with RAD001 20nM alone for 48h also 
achieved a significant decrease on cell viability compared to the control 
(64.2±16.8%; p=0.01). Treatment with DCA 35mM in combination with RAD001 
20nM or with vemurafenib 5 and 10µM achieved a significant reduction of the 
percentage of viable cells (29.5±8.9%, 15.6±7.4 and, 14.7±8.3, respectively) 
compared to the control (p<0.01), when compared to DCA 35mM plus RAD001 
20nM treatment with RAD001 alone (p=0.02) and also when compared DCA 
35mM plus vemurafenib 5 and 10µM treatment with vemurafenib 5 and 10µM 
alone (p<0.01), after 48h of treatment. Treatment with RAD001 20nM combined 
with vemurafenib 5 and 10µM also decrease significantly the percentage of viable 
cells compared to the control (66.5±7.7% and 61.8±9.6%, respectively; p<0.01), 
although in comparison with vemurafenib 5 and 10µM combined with DCA 35mM 
treatments, the decreased in cell viability was significantly smaller (p<0.01), after 
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48h of treatment. In this cell line, similar percentages of cell viability were 
observed after 72h of each treatment (Fig. 5C). 
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Figure 5: A, B and C) Graphic representation of the percentage of viable cells of A375 (A), Mewo 
(B) and ED013R2 (C) melanoma cell lines treated with DCA, RAD001 and vemurafenib, and 
combined treatments with different concentrations of the three drugs for 48 and 72h, determined by 
Presto Blue assay. DCA35 (DCA 35mM); RAD5, RAD10, RAD15, RAD20 (RAD001 5, 10, 15 and 
20nM); Vem44, Vem88, Vem132, Vem175, Vem1.25, Vem2.5, Vem3.75, Vem5, Vem10 
(vemurafenib 44, 88, 132 and 175nM for A375 (A), 1.25, 2.5, 3.75 and 5µM for Mewo (B), and 5 
and 10µM for ED013R2 (C)); D35R5, D35R10, D35R15, D35R20 (DCA 35mM, RAD001 5, 10, 15 
and 20nM); D35V44, D35V88, D35V132, D35V175, D35V1.25, D35V2.5, D35V3.75, D35V5, 
D35V10 (DCA 35mM, vemurafenib 44, 88, 132 and 175nM for A375 (A), 1.25, 2.5, 3.75 and 5µM 
for Mewo (B), and 5 and 10µM for ED013R2 (C)); R20V44, R20V88, R20V132, R20V175, 
R20V1.25, R20V2.5, R20V3.75, R20V5, R20V10 (RAD001 20nM, vemurafenib 44, 88, 132 and 
175nM for A375 (A), 1.25, 2.5, 3.75 and 5µM for Mewo (B), and 5 and 10µM for ED013R2 (C)).The 
data are presented as mean±SD. * refers to significant (p≤0.05) difference when comparing cells 
treated to non-treated cells. 
 
4.2 Effects of DCA, RAD001 and vemurafenib treatment on proliferation of 
melanoma cell lines  
To evaluate the effects of DCA, RAD001 and vemurafenib on cell proliferation, the 
number of cells was counted after 72h of treatment with these therapeutic agents, 
either alone or in combination.  
After DCA treatment, a decrease in the number of cells was observed in all three 
cell lines, with a higher reduction in A375 (p<0.01) followed by ED013R2 and 
Mewo (p<0.01) (Fig. 6A, B and C). 
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After A375 treatment with RAD001 10 and 20nM, no significant alteration on cell 
proliferation was observed (Fig. 6A). The number of cells decreases in A375 cell 
line treated with concentrations of 88 and 175nM of vemurafenib compared to the 
control (not significant and p<0.01, respectively). In A375 cell line, combined 
therapy leaded to a higher decrease number of cells after 72h of treatment. 
Combinations of DCA 35mM with RAD001 10 and 20nM or, with vemurafenib 88 
and 175nM, significantly decreases the number of cells compared to the control 
(p<0.01), when compared DCA 35mM plus RAD001 10 and 20nM treatment with 
RAD001 10 and 20nM alone (p<0.01) and also when compared DCA 35mM plus 
vemurafenib 88 and 175nM treatment with vemurafenib 88 and 175nM alone (not 
significant and p=0.02, respectively). Treatment with RAD001 20nM combined with 
vemurafenib 88 and 175nM also decrease the number of cells in comparison with 
the control (p<0.01) and when compared with vemurafenib 88 and 175nM 
combined with DCA 35mM treatments, the decreased in cell viability was smaller, 
although not reaching significance (Fig. 6A). 
In Mewo cell line, treatment with RAD001 10 and 20nM alone reduced significantly 
the number of cells compared to the control (p<0.01). Treatment with vemurafenib 
2.5 and 5µM did not alter the number of cells significantly comparing with the 
control. In Mewo cell line, the higher cell number reduction was achieved with 
combined therapy of DCA with both RAD001 (10 and 20nM) and vemurafenib (2.5 
and 5µM), reaching significance compared to the control (p<0.01; p<0.01; p=0.02 
and p<0.01, respectively) (Fig. 6B). Also, a significant decrease was observed 
comparing DCA 35mM plus RAD001 10 and 20nM treatment with RAD001 10 and 
20nM alone (p<0.01) and also comparing DCA 35mM plus vemurafenib 2.5 and 
5µM treatment with vemurafenib 2.5 and 5µM alone (p<0.01). Treatment with the 
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combination of RAD001 20nM with vemurafenib 2.5 and 5µM reduced the number 
of cells compared to the control (not significant and p<0.01) and compared with 
vemurafenib 2.5 and 5µM combined with DCA 35mM treatments, the decrease in 
the cell number was smaller (not significant and p<0.01). 
In the vemurafenib resistant cell line, ED013R2, all treatments decrease the 
number of cells comparing to the control. Treatment with RAD001 10 or 20nM 
alone and vemurafenib 5 and 10µM alone reduced the number of cells compared 
to the control (Fig. 6C). Treatments combining DCA 35mM with RAD001 (10 and 
20nM) and vemurafenib (5 and 10µM) reached a high rate of cell number 
reduction. Also, a significant decrease was observed comparing DCA 35mM plus 
RAD001 10 and 20nM treatment with RAD001 10 and 20nM alone and also 
comparing DCA 35mM plus vemurafenib 5 and 10µM treatment with vemurafenib 
5 and 10µM alone. Treatments with RAD001 20nM in combination with 
vemurafenib 5 or 10µM also reduced the number of cells compared to the control, 
although with a smaller decrease comparing with vemurafenib 5 and 10µM 
combined with DCA 35mM treatment (Fig. 6C). 
 
 
  
 
 
 
 
 
 
A375 
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Figure 6: Graphic representation of the mean number of cells of A375 (A), Mewo (B) and 
ED013R2 (C, based in a single experiment) melanoma cell lines treated with DCA, RAD001 and 
vemurafenib, and combined treatments with different concentrations of the three drugs for 72h, 
determined by direct cell count. DCA35 (DCA 35mM); RAD10, RAD20 (RAD001 10 and 20nM); 
Vem88, Vem175, Vem2.5, Vem5, Vem10 (vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM 
for Mewo (B), and 5 and 10µM for ED013R2 (C)); D35R10, D35R20 (DCA 35mM, RAD001 10 and 
20nM); D35V88, D35V175, D35V2.5, D35V5, D35V10 (DCA 35mM, vemurafenib 88 and 175nM for 
A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 10µM for ED013R2 (C)); R20V88, R20V175, 
R20V2.5, R20V5, R20V10 (RAD001 20nM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM 
for Mewo (B), and 5 and 10µM for ED013R2 (C)). The data are presented as mean±SD. * refers to 
significant (p≤0.05) difference when comparing cells treated to non-treated cells. 
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4.3 Effects of DCA, RAD001 and vemurafenib treatment in cell cycle of 
melanoma cell lines  
To clarify the mechanism of action of DCA, RAD001 and vemurafenib, alone 
and/or in combination, cell cycle analysis were performed in the three cell lines, 
after 72h of treatment with these therapeutic agents. 
In A375 cell line, comparing with the control, treatment with single drugs 
vemurafenib 88 and 175nM had higher percentage of cells in G0/G1 (84.4±5.9%; 
p=0.03 and 83.1±7.5%; p=0.05, respectively) than treatments with RAD001 10 and 
20nM (76.8±4.4% and 75.8±3.5%, respectively, not significant). Similar results 
were achieved with treatment with DCA 35mM, alone or in combination, with 
RAD001 10 and 20nM and vemurafenib 88 and 175nM, showing a higher 
percentage of cells in G0/G1 phase comparing with the control (88.9±7.1%; 
p=0.02, 89.3±6.6%; p=0.01, 88.1±9.1%; p=0.05, 91.2±5.2%; p=0.02 and 
88.5±5.4%; p=0.02), although with non-significant differences between treatments. 
In this cell line, all combined treatments increase the percentage of cells in G0/G1 
phase in comparison with treatment with single drugs, although not reaching 
statistical significance. The number of cells in S and G2/M phases was lower in all 
treatments compared to the control, although the some did not reach a significant 
difference (Fig. 7A). 
In Mewo cell line, treatment with DCA 35mM alone had a tendency for increase 
the percentage of cells in G0/G1 phase, although not reaching statistical 
significance. Comparing with the control, treatment with single drug RAD001 10 
and 20nM (61.0±4.7% and 62.8±7.3%, respectively, not significant) had higher 
percentage of cells in G0/G1 than treatments with vemurafenib 2.5 and 5µM 
(56.4±4.4%; not significant and 60.4±0.8%; p=0.01, respectively). In Mewo cell 
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line, all the treatments with combined therapies had higher percentage of cells in 
G0/G1 phase than the treatments with therapeutic agents alone. This difference 
only reach significance in treatments combining RAD001 20nM with vemurafenib 
2.5 and 5µM (66.1±3.0%, 68.6±4.1%) that had higher percentage of cells in G0/G1 
phase than treatments with vemurafenib 2.5 and 5µM alone (p=0.01 and p=0.02, 
respectively). DCA 35mM and RAD001 20nM, each in combination with 
vemurafenib 2.5 and 5µM, increase the percentage of cells in G0/G1 compared to 
the control (64.1±5.6%, p=0.04; 68.8±7.2%, p=0.02 and 66.1±3.0%, p<0.01; 
68.6±4.1%, p<0.01, respectively), and non-significant differences were achieved 
between treatments. The number of cells in S and G2/M phases was lower in all 
treatments comparing with the control, and the majority of the treatments reached 
a significant reduce number of cells compared to the control (Fig. 7B).In ED013R2 
cell line, comparing with the control, treatment with single drug RAD001 10 and 
20nM (74.6±4.9%, not significant and 79.1±3.6%, p=0.04, respectively) had similar 
percentage of cells in G0/G1 than treatments with vemurafenib 5 and 10µM 
(72.4±0.3%; p=0.01 and 78.6±3.8%; p=0.04, respectively). The higher 
percentages of cells in G0/G1 phase, comparing with the control, were reached in 
treatment with combined therapies of RAD001 20nM plus vemurafenib 5 and 
10µM (87.2±2.8% and 85.7±0.0%, respectively; p<0.01). The number of cells in S 
and G2/M phases was lower in all treatments compared to the control, although in 
the S phase almost all treatments reached a significant reduce number of cells 
compared to the control, contrarily to G2/M phase, where the majority did not 
reach a significant difference (Fig. 7C). 
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Figure 7: Graphic representation of the cell cycle analysis of A375 (A), Mewo (B) and ED013R2 
(C) cells non-treated or treated with DCA, RAD001 and vemurafenib, and combined treatments 
DCA as a possible therapy for cutaneous melanoma in combination with approved therapeutics 
 
44 
 
with different concentrations of the three drugs for 72h, determined by Flow cytometry. DCA35 
(DCA 35mM); RAD10, RAD20 (RAD001 10 and 20nM); Vem88, Vem175, Vem2.5, Vem5, Vem10 
(vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 10µM for 
ED013R2 (C)); D35R10, D35R20 (DCA 35mM, RAD001 10 and 20nM); D35V88, D35V175, 
D35V2.5, D35V5, D35V10 (DCA 35mM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for 
Mewo (B), and 5 and 10µM for ED013R2 (C)); R20V88, R20V175, R20V2.5, R20V5, R20V10 
(RAD001 20nM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 
10µM for ED013R2 (C)). The data are presented as mean±SD. * refers to significant (p≤0.05) 
difference when comparing cells treated to non-treated cells. 
 
4.4 Effects of DCA, RAD001 and vemurafenib treatment in apoptosis of 
melanoma cell lines 
The effects of DCA, RAD001 and vemurafenib treatments were evaluated on cell 
apoptosis in the three cell lines after 72h of treatment.  
A significant increase in the percentage of apoptotic cells was found, after 72h of 
treatment with 35mM of DCA, in all three cell lines (p<0.01).  
In A375 cell line, treatment with single drug RAD001 10 and 20nM (6.6±4.9%, and 
9.0±5.0%, respectively) leaded to a similar increase of the percentage of apoptotic 
cells than treatment with vemurafenib 88 and 175nM (9.3±7.4% and 9.1±3.8%, 
respectively), although not reaching significance comparing with the control (Fig. 
8A). In A375 cell line, the percentage of apoptotic cells was significantly increase 
compared to the control, in treatments combining DCA 35mM with RAD001 10nM 
(29.6±2.0%; p<0.01) and 20nM (21.7±2.8%; p<0.01), and with vemurafenib 88nM 
(21.4±0.9%; p<0.01) and 175nM (38.5±4.0%; p<0.01). The rate of apoptotic cells 
was higher in cells treated with DCA 35mM combined with RAD001 10nM than in 
cells treated with DCA 35mM alone (29.6±2.0% and 12.3±2.2%, respectively; 
p=0.01). Treatment with the combination of RAD001 20nM with vemurafenib 88 
and 175nM (16.1±6.3% and 20.5±4.2%, respectively) increase the percentage of 
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apoptotic cells compared to the control (p=0.03 and p<0.01) and compared with 
vemurafenib 88 and 175nM combined with DCA 35mM treatment, this increase in 
the percentage of apoptotic cells was smaller (not significant and p=0.02). 
Combination of DCA 35mM with vemurafenib 175nM achieved the higher mortality 
rate in A375 cell line (Fig. 8A). 
In Mewo cell line, comparing with the control, treatment with single drug RAD001 
10 and 20nM (3.9±0.6%; p=0.05 and 5.1±0.9%; p=0.02, respectively) leaded to a 
similar increase of the percentage of apoptotic cells than treatment with 
vemurafenib 2.5 and 5µM (4.4±0.6%; p=0.02 and 3.6±0.5%; not significant, 
respectively) (Fig. 8B). In this cell line, the percentage of apoptotic cells was 
significantly increase compared to the control, in treatments combining DCA 
35mM with RAD001 10nM (6.0±1.3%; p=0.01) and 20nM (4.8±0.4%; p<0.01), and 
with vemurafenib 2.5µM (8.3±1.9%; p=0.01) and 5µM (7.5±2.2%; p=0.02). 
Treatment with the combination of RAD001 20nM with vemurafenib 2.5 and 5µM 
(6.9±1.3% and 6.9±1.7%, respectively) increase the percentage of apoptotic cells 
compared to the control (p<0.01 and p=0.01), similarly to the percentage obtained 
with the treatment of vemurafenib 2.5 and 5µM combined with DCA 35mM (Fig. 
8C). 
In ED013R2 cell line, an increase on apoptosis was achieved with treatment with 
RAD001 10 and 20nM (not significant), vemurafenib 5 and 10µM (not significant 
and p=0.04) and combination of RAD001 20nM with vemurafenib 5 and 10µM (not 
significant and p=0.04, respectively), after 72h of treatment, compared to the 
control. Treatments with DCA 35mM, either alone or in combination with RAD001 
10 or 20nM and vemurafenib 5 or 10µM, significantly increase the number of 
apoptotic cells compared to the control (31.9±2.4%, 33.5±2.8%, 37.6±1.3%, 
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59.7±2.6% and, 77.0±1.5%; p<0.01, respectively). The higher rate of mortality was 
achieved in ED013R2 cell line treated with DCA 35mM combined with 
vemurafenib 10µM (Fig. 8C). 
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Figure 8: Graphic representation of the percentage of apoptotic A375 (A), Mewo (B) and ED013R2 
(C) cells non-treated or treated with DCA, RAD001 and vemurafenib, and combined treatments 
with different concentrations of the three drugs for 72h, determined by Flow cytometry. DCA35 
(DCA 35mM); RAD10, RAD20 (RAD001 10 and 20nM); Vem88, Vem175, Vem2.5, Vem5, Vem10 
(vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 10µM for 
ED013R2 (C)); D35R10, D35R20 (DCA 35mM, RAD001 10 and 20nM); D35V88, D35V175, 
D35V2.5, D35V5, D35V10 (DCA 35mM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for 
Mewo (B), and 5 and 10µM for ED013R2 (C)); R20V88, R20V175, R20V2.5, R20V5, R20V10 
(RAD001 20nM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 
10µM for ED013R2 (C)). The data are presented as mean±SD. * refers to significant (p≤0.05) 
difference when comparing cells treated to non-treated cells. 
 
4.5 Effects of DCA, RAD001 and vemurafenib treatment in MAPK and mTOR 
pathways effectors, and in HIF1-α expression in melanoma cell lines  
The efficacy of DCA, RAD001 and vemurafenib treatments, alone or in 
combination, in inhibiting MAPK and mTOR pathways, was evaluated by analyzing 
the expression of the phosphorylated downstream effectors of both signaling 
pathways on the three cell lines. Also, the expression of possible DCA targets, 
PDH and HIF1-α, were evaluated. A representative western blot panel of protein 
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expression, observed in A375 melanoma cell line, can be found in supplementary 
figure 1 (Appendices). 
After 72h of DCA treatment, significant inhibition of the phosphorylation of PDH 
was observed in the three cell lines (p<0.01) and an even higher inhibition was 
achieved in all DCA 35mM combinations (p<0.01) (Fig. 9). 
HIF1-α expression was evaluated. For A375 cell line, a significant decrease on the 
levels of HIF1-α were achieved after treatment with RAD001 20nM alone (p<0.01) 
and also after treatment with vemurafenib 88nM, either alone or in combination 
with DCA 35mM and RAD001 20nM (p=0.03; p<0.01 and, p=0.02, respectively) 
(Fig. 9A). In Mewo cell line, a significant decrease was observed after treatment 
with DCA 35mM (p=0.02), RAD001 10 and 20nM (p<0.01) (Fig. 9B). A decrease 
on the expression level of HIF1-α was also observed in ED013R2 cell line after 
treatment with DCA 35mM alone and in combination with RAD001 20nM (p<0.01 
and p=0.02, respectively) (Fig. 9C). 
Expression level of phosphorylated mTOR was evaluated in A375 and Mewo cell 
lines. In A375 cell line, treatment with RAD001 20nM, either alone or in 
combination with vemurafenib 88 and 175nM, significantly decrease the 
expression level of phosphorylated mTOR, compared to the control (p<0.01, 
p<0.01 and p=0.02, respectively). Increase expression of phosphorylated mTOR 
was achieved in cells treated with DCA 35mM combined with vemurafenib 88nM 
(p=0.02) (Fig. 9A). In Mewo cell line, a significant decrease on phosphorylated 
mTOR was achieved after treatment with RAD001 20nM, alone or combined with 
DCA 35mM and vemurafenib 2.5 and 5µM (p<0.01, p=0.01, p=0.02 and p<0.01). 
The same effect was observed in cells treated with RAD001 10nM combined with 
DCA 35mM (p<0.01) (Fig. 9B). 
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The levels of phosphorylated AKT (Ser473) were evaluated. Generally, all 
treatments enhanced the levels of the phosphorylate form of AKT, in the three cell 
lines. In A375 cell line, the higher significant enhancement was achieved in cells 
treated with DCA 35mM alone (p<0.01) or in combination with RAD001 10 and 
20nM (p=0.05 and p<0.01, respectively) and vemurafenib 175nM (p=0.03). Also, 
RAD001 10 and 20nM alone (p=0.04 and p=0.03), and RAD001 20nM combined 
with vemurafenib 88 and 175nM (p=0.01 and not significant, respectively) increase 
the expression of phosphorylated AKT (Fig. 9A). In Mewo cell line this increased 
level of expression of phosphorylated AKT was more significant with DCA 35mM 
combined with RAD001 10nM (p=0.01), with RAD001 10 and 20nM (p<0.01) and, 
with RAD001 20nM combined with vemurafenib 5µM (p=0.05). The treatment with 
DCA 35mM alone or in combination with RAD001 20nM also increase the level of 
expression of phosphorylated AKT, although not reaching significance (Fig. 9B). In 
ED013R2 cell line, the enhancement on phosphorylation of AKT was more evident 
in cells treated with DCA 35mM alone or combined with RAD001 10nM (p<0.01), 
RAD001 20nM alone or combined with vemurafenib 5 and 10µM (p<0.01), and 
with vemurafenib 10µM alone (p=0.03) (Fig. 9C). 
The expression of the readout of mTOR pathway activation, S6, was also 
evaluated. The expression level of the phosphorylate form of S6 was significantly 
decrease in the three cell lines. In A375 and Mewo cell lines, this decrease was 
significant when cells were treated with RAD001 10 and 20nM alone, DCA 35mM 
combined with RAD001 10 and 20nM and, RAD001 20nM combined with 
vemurafenib (88 and 175nM for A375, and 2.5 and 5µM for Mewo) comparing with 
the control (p<0.01) (Fig. 9A and B). In ED013R2 cell line, also a decrease on the 
levels of phosphorylated S6 was achieved with treatment with RAD001 10 and 
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20nM alone, DCA 35mM combined with RAD001 20nM, and RAD001 20nM 
combined with vemurafenib 5 and 10µM (p<0.01) (Fig. 9C). 
Expression levels of BRAF were also evaluated in A375 and Mewo cell lines. No 
alterations were observed after treatment with DCA, RAD001 and vemurafenib, 
alone or in combinations (Fig. 9A and B). 
The phosphorylation of ERK1/2 was used as readout of MAPK pathway activation. 
In A375 a decrease of phosphorylated ERK1/2 expression level was observed, 
after treatment with vemurafenib 88 and 175nM, although only reaching 
significance with vemurafenib 175nM (p=0.03). Contrarily, treatment with RAD001 
20nM combined with vemurafenib 175nM significantly increase the expression 
levels of phosphorylated ERK1/2 (p=0.03) (Fig. 9A). In Mewo cell line, the same 
tendency to diminished phosphorylation of ERK1/2, after treatment with 
vemurafenib 2.5 and 5µM alone, was observed (not significant). The level of 
expression of phosphorylated ERK1/2 was not altered by any other treatments 
(Fig. 9B). In ED013R2 cell line, the expression level of phosphorylated ERK1/2 
was increased after treatment with vemurafenib 5 and 10µM alone (p<0.01), and 
DCA 35mM alone (p<0.01) or combined with RAD001 10nM (p<0.01) and 
RAD001 20nM (not significant). A significant increase level of expression was 
achieved after treatment with RAD001 20nM combined with vemurafenib 5µM, 
comparing with the control (p<0.01) (Fig. 9C). 
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Figure 9: Graphic representation of the mean fold change of activated protein expression of pPDH, 
pS6, pERKs, BRAF, HIF1-α, pAKT and pmTOR observed in A375 (A), Mewo (B) and ED013R2 (C) 
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melanoma cell lines treated with DCA, RAD001 and vemurafenib, and combined treatments with 
different concentrations of the three drugs for 72h, compared to non-treated cells. DCA35 (DCA 
35mM); RAD10, RAD20 (RAD001 10 and 20nM); Vem88, Vem175, Vem2.5, Vem5, Vem10 
(vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 10µM for 
ED013R2 (C)); D35R10, D35R20 (DCA 35mM, RAD001 10 and 20nM); D35V88, D35V175, 
D35V2.5, D35V5, D35V10 (DCA 35mM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for 
Mewo (B), and 5 and 10µM for ED013R2 (C)); R20V88, R20V175, R20V2.5, R20V5, R20V10 
(RAD001 20nM, vemurafenib 88 and 175nM for A375 (A), 2.5 and 5µM for Mewo (B), and 5 and 
10µM for ED013R2 (C)). The data are presented as mean±SD. * refers to significant (p≤0.05) 
difference when comparing cells treated to non-treated cells. 
 
4.6 Effects of DCA, RAD001 and vemurafenib treatment in melanoma cell 
lines motility 
To evaluate the effects of DCA, RAD001 and vemurafenib treatment on cells 
motility, wound-healing and motility assays were performed in A375 and Mewo 
melanoma cell lines. No conclusive results were achieved with both, wound-
healing and motility experiments, as melanoma cells movement was almost 
inexistent (data not shown). 
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5 Discussion 
Nowadays, the major concern in advanced cutaneous melanoma treatment 
management is that recently approved therapies have limitations, such as fast 
acquirement of resistance to MAPK pathway inhibitors and adverse side effects 
from immunotherapeutic drugs. As cutaneous melanoma cells evidence the 
presence of the Warburg effect and display overactivation of MAPK and 
PI3K/AKT/mTOR pathways, it seems that DCA, in combination with mTOR or 
MAPK inhibitors, can be a promising new therapy for melanoma patients. 
The present work describes the major effects observed in three genetically 
different melanoma cell lines (BRAF-wildtype, BRAF-mutant and, BRAF-
mutant/vemurafenib resistant) treated with three drugs (DCA, RAD001 and 
vemurafenib), either alone or in combination. 
Vemurafenib, the MAPK pathway inhibitor, is selective for mutant BRAF, as the 
mutation favors the active enzyme conformation [82]. Concordantly, A375 
(BRAFV600) was the most sensitive cell line to this drug, achieving an IC50 lower 
than 1µM, contrary to Mewo cell line (BRAFwt) that showed an IC50 higher than 
1µM, in agreement with previous results from Hatzivassiliou et al., who reported 
similar effects on these two cell lines after treatment with an analogue of 
vemurafenib (PLX4720) [206]. The IC50 of vemurafenib was not reached for 
ED013R2 resistant cell line, even when treated with higher doses, confirming the 
specificity of the drug and the resistance of the cell line. Therefore, A375 
(BRAFV600) may be considered sensitive to vemurafenib, Mewo (BRAFwt) seems 
less sensible and for ED013R2 (BRAFV600), the resistance to the drug was 
confirmed. 
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Results obtained in cell viability assay are consistent with results from proliferation 
and apoptosis assessments. A375, Mewo and also ED013R2 cell lines seem to be 
more sensitive, achieving higher decrease in cell viability and in cell number, and 
an increase in apoptosis, with DCA combination treatments than with RAD001 or 
vemurafenib single treatment. In general, Mewo cell line was not as sensitive to 
combined therapy as A375, as the genetic background of the cell lines confers 
different sensitivity to each drug. As previously described by our group, RAD001 
alone reached higher reduction on cell viability on BRAFV600 cell lines than in 
BRAF-wildtype, although when used in combination with DCA or vemurafenib, this 
effect was potentiated in all cell lines [169]. Nevertheless, on the resistant cell line, 
the combination of RAD001 and vemurafenib does not reach major effects 
compared with either of the drugs alone, probably because the cell line is less 
dependent on BRAF oncogenic signaling. 
As expected and previously described, DCA and RAD001, alone or in 
combination, leaded to cell cycle arrest in G0/G1 phase, in all analyzed cell lines, 
and concordantly, the percentage of cells on S phase and G2/M phase was 
decreased [169, 199]. Preclinical evidence of anticancer effect of DCA was 
reported by Bonnet et al. that suggested that the promotion of glucose 
consumption and ROS production by DCA may be responsible for the cell cycle 
arrest in G0/G1 phase [204], as the levels of glycolysis are involved in cell cycle 
progression and additionally, cancer cells cannot manage the increased oxidative 
stress, leading to cell cycle arrest and increase apoptosis [207, 208]. The same 
effect was observed after RAD001 treatment. This drug inhibits ribosome 
biogenesis and global translation, by blocking the phosphorylation of mTOR 
effectors, leading to a decreased in cyclin D1 expression and increased p27 
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expression that block G1/S cell cycle transition [131, 134, 209]. Vemurafenib 
treatment alone, or in combination, lead to G0/G1 phase arrest only in the two cell 
lines BRAFV600 (A375 and ED013R2), regardless to their in vitro sensitivity to the 
drug. No effect was observed in melanoma cell line BRAF-wild type (Mewo), as 
also observed by Sondergaard et al. As vemurafenib prove to be a potent inhibitor 
of the BRAF mutant kinase, leading to a decrease on cell proliferation and an 
increase on apoptosis through reduction of phosphorylated ERK and cyclin D1, a 
protein highly important to G1/S cell cycle transition, there is a higher efficiency in 
BRAF-mutant than in BRAF-wildtype cell lines [82]. 
As expected, the expression levels of the readouts of each drug, phosphorylation 
of PDH, S6 and ERK1/2 [82, 169, 199], were diminished after treatment with DCA, 
RAD001 and vemurafenib, respectively, in all analyzed cell lines. 
In ED013R2 cell line, the levels of expression of phosphorylated ERK1/2 
increased after DCA and vemurafenib treatment. The resistance to vemurafenib, 
as already discuss, may allow a reduce dependence on BRAF oncogenic signaling 
and the activation of MAPK pathway by other secondary oncogenic events 
besides BRAF [94, 104]. Also, after treatment with RAD001 combined with 
vemurafenib, the levels of phosphorylated ERK1/2 were increased in the BRAF-
mutant cell line (A375). The inhibition of mTOR or MAPK pathway leads to a 
mutual negative-feedback loop mediated by S6K1 or ERKs/IRS-1 with the 
induction of upstream receptor tyrosine kinase signaling, being each pathway able 
to inhibit or activate the other [165, 210, 211]. As A375 was the most sensitive cell 
line to the treatments because of its genetic background, as previously discussed, 
the combination of the drugs may have a cumulative effect, promoting a high 
activation of the negative-feedback loop. The same mechanism was already 
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described to be responsible for the increased levels of phosphorylation of AKT 
observed in all cell lines after RAD001 treatment [165], again more pronounced in 
A375 cell line. Also, the increase levels of phosphorylated AKT observed in the 
three cell lines is concordantly with the insensitivity of mTORC2 complex to 
RAD001 treatment, which is the upstream effector of this phosphorylation [152, 
212, 213]. The sensitivity of mTORC1 was observed by the reduction of the levels 
of phosphorylation of S6 and mTOR, suggesting that RAD001 is in fact effectively 
blocking the mTOR pathway in melanoma cell lines [169, 214]. Although it was not 
obvious in the present work, in previous work from our group, DCA appears to 
decrease mTOR pathway activation, which may explain the increased 
phosphorylated AKT level observed after DCA treatment. 
As DCA inhibits PDK, which when activated produce mitochondrial signals that 
lead to HIF1-α activation in cancer, even in normoxic conditions, the hypoxic 
phenotype is reverted leading to a decrease of HIF1-α activation [203, 215]. 
Concordantly, in our work, a decrease in HIF1-α level after DCA treatment was 
observed in all melanoma cell lines, as previously reported [203, 216, 217]. Not 
surprisingly, a decrease on HIF1-α expression after RAD001 treatment was 
observed. This effect was previously reported and is probably due to HIF1-α 
regulation by the mTOR pathway [150, 151].  
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6 Conclusion 
DCA prove to be an efficient therapeutic agent in cutaneous melanoma treatment, 
either alone or in combination with MAPK and mTOR pathways inhibitors. DCA 
combined with vemurafenib showed to be the more effective treatment, blocking 
cell proliferation, decreasing cell viability, increasing apoptosis and downregulating 
MAPK and mTOR pathways, for all the analyzed cell lines. The MAPK and mTOR 
pathway inhibitors prove to affect cell dynamics, being this effects highly 
potentiated when combined with DCA. Combination of MAPK and mTOR inhibitors 
also evidence promising effects above cell cycle, proliferation and apoptosis, 
although the activation of secondary survival pathways seems to occur, lowering 
the therapy efficacy. 
This work reinforce the concept that strategies for melanoma therapy should 
consider the BRAF mutational status, and a genetic screening of each patient 
should be done for a personalized therapy, hopefully leading to an improvement of 
survival. 
Our work provide strong evidences that resistance to vemurafenib may be 
reversed through combination of BRAF inhibition with a metabolic modulator as 
DCA, that potentiate vemurafenib effect, via a cooperative attenuation of energy 
production, although further studies are needed in order to confirm and validate 
this evidence.  
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8 Appendices 
8.1 Supplementary table 1 
 
Supplementary table 1: Cutaneous melanoma staging [218] 
Stage T N M Clinical-Histopathological Features 
0 Tis N0 M0 In situ melanoma (intraepithelial) 
IA T1a N0 M0 ≤1 mm without ulceration 
IB 
T1b N0 M0 ≤1 mm with ulceration 
T2a N0 M0 1.01-2 mm without ulceration 
IIA 
T2b N0 M0 1.01-2 mm with ulceration 
T3a N0 M0 2.01-4 mm without ulceration 
IIB 
T3b N0 M0 2.01-4 mm with ulceration 
T4a N0 M0 4 mm without ulceration 
IIC T4b N0 M0 4 mm without ulceration/ >4 mm with ulceration 
IIIA 
T1-4a N1a M0 Single regional nodal micrometastasis, without ulceration 
T1-4a N2a M0 2-3 microscopic positive regional nodes, without ulceration 
IIIB 
T1-4b N1a M0 Single regional nodal micrometastasis, with ulceration 
T1-4b N2a M0 2-3 microscopic positive regional nodes, with ulceration 
T1-4a N1b M0 Single regional nodal macrometastasis, without ulceration 
T1-4a N2b M0 2-3 macroscopic regional nodes, without ulceration 
T1-4a/b N2c M0 
In-transit met(s)/ satellite lesion(s) without metastatic lymph 
nodes 
IIIC 
T1-4b N1b M0 Single regional nodal macrometastasis, with ulceration 
T1-4b N2b M0 2-3 macroscopic regional nodes, with ulceration 
Any T N3 M0 
4 or more metastatic nodes, matted nodes, or in-transit 
met(s)/satellite lesion(s) with metastatic nodes 
IV Any T Any N Any M1 
M1a: Distant skin, subcutaneous, or nodal mets with normal 
LDH levels 
M1b: Lung metastases with normal LDH 
M1c: All other visceral metastases with normal LDH or any 
distant metastasis with elevated LDH 
Legend: T=tumor size; N=node status; M=metastasis; Ta=without ulceration; Tb=with ulceration 
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8.2 Supplementary figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary figure 1: Representative western blot analysis of pPDH, PDH, pS6, S6, pERKs, 
ERKs, BRAF, HIF1-α, pAKT, AKT, pmTOR and mTOR expression observed in A375 melanoma 
cell line treated with DCA, RAD001 and vemurafenib, and combined treatments with different 
concentrations of the three drugs for 72h, compared to non-treated cells. DCA (DCA 35mM); R10, 
R20 (RAD001 10 and 20nM); V88, V175 (vemurafenib 88 and 175nM); DR10, DR20 (DCA 35mM, 
RAD001 10 and 20nM); DV88, DV175 (DCA 35mM, vemurafenib 88 and 175nM); RV88, RV175 
(RAD001 20nM, vemurafenib 88 and 175nM). 
